Expert Interview
Discussing Fractyl Health's results from the REMAIN-1 Midpoint Cohort evaluating the Revita procedure in patients with obesity and type 2 diabetes following discontinuation of GLP-1 therapy
Ticker(s): GUTS, NVO, LLYInstitution: University of Utah Medical Center
- Director of the Obesity Medicine Program and Co-Director of the Comprehensive Weight Management Program at the University of Utah.
- Treats 200 patients a month with obesity (100 with Type 2 Diabetes).
- Research and clinical interests in medical weight management, genetics of obesity, and chronic disease management.
Based on the REMAIN-1 midpoint findings, what do you see as the most important clinical implication of Revita for patients with obesity and type 2 diabetes who have discontinued GLP-1 therapy?
Added By: sara_adminGiven these interim results, what additional data or long-term outcomes will be most important to determine Revita’s future role in metabolic disease management?
Added By: sara_adminOn a scale from 1-10 (10 being extremely excited) how would you rate your level of excitement for Revita?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
